Posted on

Q&M Group awards 7 dentists with Performance Shares,12-year Service Agreements, and a Private Placement

SINGAPORE, Sep 30, 2022 - (ACN Newswire via SEAPRWire.com) - Mainboard-listed Q&M Dental Group (Singapore) Limited [SGX: QC7] announced on 29 September 2022 the award of 2,014,245 shares to 7 promising next-generation dentists as part of the Q&M Performance Share Plan (PSP) 2018, as well as the proposed placement of an additional 4,985,755 treasury shares, totalling S$1.75 million, through placement to the same dentists.These 7 Key Dentists are the recipients of awards under the PSP 2018 by Q&M in its announcement dated 29 September 2022. These Key Dentists have also expressed their interest to subscribe for further shares as an expression of their confidence in and their commitment to the continued success of the company. They intend to enter into an arrangement similar to that entered into between the founding dentists of the Group in respect of Q&M's controlling shareholder, Quan Min Holdings Pte. Ltd., in order to hold their Shares in Q&M.The placement of 4,985,755 treasury shares at a price of 35.1 Singapore cents is based on the volume weighted average price (VWAP) for trades done on the shares of Q&M on the Singapore Exchange for the full market day on 29 September 2022, being the market day on which the Placement Letters were executed. This amounts to a gross consideration of S$1.75 million."The Board is heartened by the decision of these Key Dentists to cement their association with the Company in tying their long-term futures with the future success of Q&M Dental Group. These high-performing dentists represent some of the very best of the Company's dentists and the quality of their work is demonstrated on a day-to-day basis. We are very pleased to see them take this next major step. The Company's next generation management could even be among them!" said Dr Ng Chin Siau, CEO, Q&M Dental Group.The Board is approached from time to time by its dentists who seek opportunities to participate in the growth of Q&M through equity investments. Share-based incentive schemes such as PSP 2018 Plan are somewhat limited in scope and do have a direct impact on Q &M's bottom line.Q&M's Board is thus of the view that a placement exercise to its own dentists brings greater benefit to the Group in the following ways:- Allows key dentists to participate in the equity of Q&M by investing their own funds, thereby aligning their interests with those of the Group. This alignment of interest promotes greater dedication, loyalty and higher standards of performance amongst dentists; and- Strengthens the capital base of Q&M and increases Q&M's public spread, which has the potential to improve the level of trading liquidity of its Shares.Dr Karan Singh Ubhi (one of the 7 Key Dentists) said, "We are grateful for the opportunity given by the Board to participate in the success of the Company and appreciate also the recognition of the work and effort that we have put in. We are firmly committed to the continued success of Q&M Dental Group and hope to contribute positively to its growth going forward."The Board believes that the Proposed Placement provides an effective way of motivating the Key Dentists to maximise their performance by investing in the Group's future, which will result in creating better value for Q&M and its shareholders.Dr Tabitha Foo, another of the 7 dentists said: "Having worked at Q&M, I have witnessed first-hand, the commitment of the management in identifying and grooming the next generation of leaders and am extremely proud to be given the opportunity to participate in this share placement and having a personal stake in the success of Q&M."Q&M board of directors understands that the Key Dentists are in the process of incorporating a new company, "Quan Min Plus 2 Pte. Ltd." to hold their Shares. The Board further notes that a similar voluntary arrangement was entered into previously by another 9 next-gen dentists on the Group through a company called Quan Min Plus Pte. Ltd., as announced by the Company on 23 October 2020.Q&M intends to use all of the Net Proceeds of approximately S$1.70 million raised for its general working capital purposes, such as business expansions, acquisitions and/or paying off loans.The Board and management of Q&M will continue to work hard in identifying the best talent within the Company, with the aim of mentoring their growth, grooming some of them to positions of leadership, while also giving them direct opportunities to participate in the growth of the Company in line with their corporate mission.About Q&M Dental Group (Singapore) Limited [SGX QC7.SI] [BIC QNM:SP] [RIC QMDT:SI]Q&M Dental Group (Singapore) Limited (QC7.SI) ("Q&M" or together with its subsidiaries, the "Group") is a leading private dental healthcare group in Asia.The Group owns the largest network of private dental outlets in Singapore, operating 106 dental outlets across the country. Underpinned by about 270 experienced dentists and over 350 supporting staff, the Group sees an average of 40,000 patient visits a month in Singapore. The Group also operates 5 medical clinics and a dental supplies and equipment distribution company.Outside of Singapore, the Group has 45 dental clinics and a dental supplies and equipment distribution company in Malaysia, as well as a dental clinic in the People's Republic of China ("PRC"). Q&M is also the substantial shareholder of Aoxin Q&M Dental Group Limited, a dental Group listed on the Catalist board of the Singapore Exchange that operates dental clinics and hospitals primarily in the north- eastern region of the PRC. The Group aims to expand its operations geographically and vertically through the value chain in Malaysia, the PRC and within the ASEAN region.The Q&M College of Dentistry was established in 2019 to offer postgraduate dental education as part of its commitment to continual education and professional development of dentists. It offers Singapore's first private postgraduate diploma programme in clinical dentistry.In 2020, the Group expanded into the medical laboratories and research industry with the strategic investment into Acumen Diagnostics Pte. Ltd. ("Acumen"). Acumen currently focuses on the manufacture, sale and distribution of COVID-19 diagnostic test kits, as well as COVID-19 testing. It is also working to roll out a pipeline of new tests, including PCR assays for dengue, sepsis and, identification of bacterial pathogens and their associated antibiotics resistance in pneumonia and bloodstream infections.EM2AI Pte Ltd, a wholly-owned subsidiary of the Group that focuses on developing AI-powered solutions to diagnosis and treatment planning has rolled out IDMS, enabling dentists within the Group's network to administer ethical treatment plans for patients.The Group was listed on the Mainboard of the Singapore Exchange Securities Trading Limited ("SGX- ST") on 26 November 2009. For more information on the Group, please visit www.QandMDental.com.sgSGX Links Reference:- Press Release: https://tinyurl.com/sgx-qm-20220930-pr- Treasury Shares: https://tinyurl.com/sgx-qm-20220930-tres- Employee Stock Options: https://tinyurl.com/sgx-qm-20220930-esoFor more information, please contact:Waterbrooks Consultants Pte LtdWayne KooTel: +65 9338-8166Email: wayne.koo@waterbrooks.com.sg Derek YeoTel: +65 9791-4707Email: derek@waterbrooks.com.sgProud Investor Relations partner: https://www.waterbrooks.com.sg/ and https://www.shareinvestorholdings.com/ Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Restricted Shares Will be Lifted on 22 September, and the Management and Investors of Arrail Group are “Hoarding”, Release High Growth Signals

HONG KONG, Sep 22, 2022 - (ACN Newswire via SEAPRWire.com) - The restricted shares of Arrail Group Limited ("Arrail Group" or the "Company", stock code: 06639.HK), a leading dental services group in China, will be officially lifted and listed for circulation on 22 September 2022. In this regard, the Company's management and investors clearly presented the idea of being "hoarding" and their current confidence.Arrail Group is a leading dental services group and have established a nationwide footprint in China, operating both Arrail Dental, a leading premium dental services brand, and Rytime Dental, a middle-end dental services brand. According to Frost & Sullivan Report, the Company is the largest dental service provider in China's premium private dental service market and the third largest dental service provider in China's entire private dental service market based in terms of total revenue in 2020.Institutional shareholders' confidence in long-term development is demonstrated by "not to reduce its shareholding"Based on the confidence in the industry prospect and the future development of Arrail Group, the major investors of the Company said that they would continue to hold shares. Meanwhile, as disclosed in the prospectus of the Company, approximately 31.55% of the shares held by Mr. Zou Qifang, the founder of the Company, and his management team will remain locked for 6 months until the end of March 2023.It is understood that prior to the public offering, Arrail Group has carried out several rounds of financing from January 2010 to January 2021, with the Pre-IPO Investors including KPCB China Fund, Qiming Venture Partners, OrbiMedAsia, Temasek, Goldman Sachs, Hillhouse Capital, etc. During the listing period, the Company also introduced five cornerstone investors, namely Abax, Harvest, Hudson Bay, OrbiMedAsia OrbiMed and Modern Dental, with subscribed amount of approximately HK$507 million of shares, accounting for approximately 74.66% of the offering shares as per the IPO Price with a lock-up period of 6 months. The "no reducing shareholding" idea of the management of Arrail Group and major investors will not only help stabilise the share price of the Company, but also promote the long-term stable development of the Company and enhance investors' confidence.The scarcity and uniqueness of national chain are recognised by the marketIt is worth mentioning that few institutions can achieve the nationwide coverage with the distinguishing regional characteristics of the dental service market. The Company is the only national chain dental institution listed on the market at present. Its business is distributed in four core regions domestically, namely North China, East China, South China and West China, and 15 cities. The scarcity and uniqueness of Arrail Group are gradually being recognised.Since entering the Hong Kong Stock Connect on 5 September, both the share price and liquidity have improved significantly. On 9 September, the trading volume reached approximately 7 million shares, with over HK$63 million. The share price has increased by nearly 100% since early September. The Company's business expansion prospects and development potential are promising.The solid fundamentals and outstanding performance also added confidence for "not to reduce its shareholding". As disclosed in the financial report, affected by the news and the improvement of comprehensive strength, for the financial year ended 31 March 2022, the total number of visits of Arrail Group reached 1.559 million, representing a year-on-year increase of 13.7% from 1.371 million in the financial year 2020/2021; The total revenue was RMB1.624 billion (the same below), representing a year-on-year increase of 7.16% as compared to the financial year 2020/2021; The adjusted net profit for the year amounted to RMB66 million, up 18.0% year on year, with strong profitability.The next step of the Company's development is also worth the market's expectation. In early July, Arrail Group announced a strategic cooperation with Wuxi Tongshan. The project was completed on 1 September. In addition, the two new hospitals and six clinics in this financial year were also basically completed. It is expected that 268 chairs will be added in this financial year, representing an increase of 20% as compared to the previous financial year. The management of the Company stated that the new chairs will lay a solid foundation for the long-term development of the Company in the future.In the long run, with the implementation of the centralised purchase policy, the market gradually returns to the rational cognition of the health care service sector. As the only listed national dental chain medical institution in the market, Arrail Group is undoubtedly the first one to enjoy the market bonus. In the future, Arrail Group will continue to improve its operational capabilities and service quality, and enhance its core competitive advantages. It is expected that the results and valuation of Arrail Group will be improved, thus promoting the further development of its dental services. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Q&M Dental net profit, excluding other gains or losses, increased by 25% to S$7.2 million on S$46.8 million of revenue for quarter ended 31 March 2022

SINGAPORE, May 12, 2022 - (ACN Newswire via SEAPRWire.com) - Q&M Dental Group (Singapore) Limited, a leading private dental healthcare group in Asia, reported net profit excluding other gains or losses attributable to shareholders of S$7.2 million for the quarter ended 31 March 2022 (1Q2022) compared to S$5.8 million in the corresponding period (1Q2021).Dr Ng Chin Siau, Chief Executive Officer of Q&M Dental said, "We are heartened by our continuous strong performance in 1Q2022 following a record-setting year FY2021. Our core dental business will remain strong, and with the abolishing of most of the pandemic restrictions, a positive impact on the economy, we are looking forward to resuming our growth trajectory of expanding our network of clinics in the coming quarters."Growth & Expansion in OperationsAs at 31 March 2022, the Group's number of dental outlets in Singapore has grown to 99, from 85 as at 31 March 2021. Similarly in Malaysia, the number of dental outlets has increased to 41, as compared to 36 previously.The Group also continues to focus on its expansion into medical diagnostics, with its associated Company, Aoxin Q&M Dental Group Limited and through its recent acquisition of 49% shareholding of Acumen Diagnostics Pte. Ltd., raising Q&M's effective interest in Acumen Diagnostics from 51% to 67%. In the near term, Acumen Diagnostics' clinical testing laboratory will roll out its pipeline of new tests, including PCR assays for dengue, sepsis and, identification of bacterial pathogens and their associated antibiotics resistance in pneumonia and bloodstream infections. Its longer-term plans include the development of new vaccines.For 1Q2022, revenue contribution from dental and medical clinics was relatively unchanged with a marginal decrease of 2% to S$38.6 million, despite the challenges of the tightening of Safe Management Measures (SMM) due to the rapid spread of the Omicron variant. Revenue contribution from medical laboratory and dental equipment & supplies segment surged by 80% to S$8.2 million on the back of increased revenue from Covid-19 testing from Acumen Diagnostics, the Group's medical laboratory business, which obtained its medical laboratory license in September 2020.The Group's net profit after tax excluding other gains or losses for 1Q2022 increased by 25% to S$7.2 million, from S$5.8 million in the corresponding period last year, translating to an earnings per share of 0.69 Singapore cent.As at 31 March 2022, the Group had cash and cash equivalents of S$43.5 million with net assets of S$94.9 million. This translates to Net Asset Value per share of 10.10 cents per share.Outlook & Further Expansion PlansWith the opening up of the Singapore economy gathering pace in 2022, the country expects to see businesses ramping up in most sectors with those that were most severely affected by the pandemic like F&B, tourism to especially benefit. The government is forecasting GDP growth of between 3.0 to 5.0% in 2022, Barring any major changes in the global macroeconomic and political situation or any new adverse developments in the evolving Covid-19 situation, the Group is cautiously optimistic on its business outlook.The Group intends to continue executing the business plans outlined below:- Expansion of network of dental clinics in Singapore and MalaysiaThe Group currently operates 99 clinics in Singapore. With the economy opening up in 2022, the Group will also intensively increase its reach through organic growth of its dental clinic network in Singapore. This will be supported by an expansion of its team of dentists to undergird the future growth of its operations in Singapore. We will continue to develop, invest and optimise our digital Artificial Intelligence (AI) guided clinical decision support system to provide the most effective and suitable treatment plans for patients. The Group believes it is well-positioned to cater to the rising demand for primary and high-value specialist dental healthcare services of its patients.Currently, the Group operates 41 clinics in Malaysia. The clinics are located in Johor (16 dental clinics), Kuala Lumpur (9 dental clinics), Selangor (11 dental clinics), Melaka (4 dental clinics) and 1 dental clinic in Negeri Sembilan.The Group intends to open at least 30 dental clinics a year from 2021 onwards in Singapore and Malaysia for the next 10 years. The eventual number of dental outlets will depend on available opportunities, pertinent market conditions and the evolving Covid-19 situation.- Expansion into private dental healthcare market in the People's Republic of China ("PRC")The main thrust of the Group's proposed expansion in PRC is through organic growth to develop a new and sustainable growth pillar that can yield long term value for the Group.- Expansion in Southeast AsiaThe Group is continuously looking out for strategic opportunities to expand its dental business and regional footprint to other Southeast Asian countries.- Medical LaboratoryThe Group will focus on rolling out its clinical testing laboratory pipeline of new tests including PCR assays for dengue sepsis and identification of bacterial pathogens and their associated antibiotics resistance in pneumonia and bloodstream infections.Please see links for PDF documents from SGXNET.Results: https://tinyurl.com/QnM-1Q2022-ResultPress Release: https://tinyurl.com/QnM-1Q-2022-ReleaseAbout Q&M Dental Group (Singapore) Limited (QC7.SI)Q&M Dental Group (Singapore) Limited (QC7.SI) ("Q&M" or together with its subsidiaries, the "Group") is a leading private dental healthcare group in Asia.The Group owns the largest network of private dental outlets in Singapore, operating 99 dental outlets across the country. Underpinned by about 290 experienced dentists and over 350 supporting staff, the Group sees an average of 40,000 patient visits a month in Singapore. The Group also operates 5 medical clinics and a dental supplies and equipment distribution company.Outside of Singapore, the Group has 41 dental clinics and a dental supplies and equipment distribution company in Malaysia, as well as a dental clinic in the People's Republic of China ("PRC"). Q&M is also the substantial shareholder of Aoxin Q&M Dental Group Limited, a dental Group listed on the Catalist board of the Singapore Exchange that operates dental clinics and hospitals primarily in the north- eastern region of the PRC. The Group aims to expand its operations geographically and vertically through the value chain in Malaysia, the PRC and within the ASEAN region.The Q&M College of Dentistry was established in 2019 to offer postgraduate dental education as part of its commitment to continual education and professional development of dentists. It offers Singapore's first private postgraduate diploma programme in clinical dentistry.In 2020, the Group expanded into the medical laboratories and research industry with the strategic investment into Acumen Diagnostics Pte. Ltd. ("Acumen"). Acumen currently focuses on the manufacture, sale and distribution of COVID-19 diagnostic test kits, as well as COVID-19 testing. It is also working to roll out a pipeline of new tests, including PCR assays for dengue, sepsis and, identification of bacterial pathogens and their associated antibiotics resistance in pneumonia and bloodstream infections.EM2AI Pte Ltd, a wholly-owned subsidiary of the Group that focuses on developing AI-powered solutions to diagnosis and treatment planning has rolled out IDMS, enabling dentists within the Group's network to administer ethical treatment plans for patients.The Group was listed on the Mainboard of the Singapore Exchange Securities Trading Limited ("SGX- ST") on 26 November 2009. For more information on the Group, please visit www.QandMDental.com.sgFor more information, please contact:Waterbrooks Consultants Pte LtdWayne KooTel: +65 9338-8166Email: wayne.koo@waterbrooks.com.sg Derek YeoTel: +65 9791-4707Email: derek@waterbrooks.com.sg Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

CATALIST-listed AOXIN Q&M records 21% growth in revenue for full year ended 31 December 2021

– EBITDA grew 47% for 12 months ended 31 Dec 2021– Proposed listing of 49%-owned Acumen Diagnostics on NASDAQ will enhance AOXIN’s shareholder value– Growth trend in revenue expected to continue as COVID-19 situation in China improves SINGAPORE, Feb 23, 2022 – (ACN Newswire) – Catalist listed Aoxin Q&M Dental Limited (“Aoxin” or “the Group”), today announced a 20.8% increase in revenue to RMB160.2 million for full year ended 31 December 2021 (“FY2021”). The Group reported a net loss after tax of RMB7.3 million for FY2021, an improvement from the net loss of RMB12.1 million from a year ago. In 2020, in view of COVID-19 situation, the Chinese government provided temporary relief to businesses by waiving the social security insurance contributions. Aoxin would have additional RMB6.3 million of social security insurance expenses recorded in FY2020 resulting in a Net Loss of RMB18.4 million, instead of RMB12.1 million. Dr. Shao Yongxin, Group Chief Executive Officer of Aoxin Q&M said, “Global economic prospects for 2022 will continue to be uncertain, with many countries still struggling to contain the rapid spread of the Omicron variant. The possibility of new COVID-19 strains cannot be ruled out. However, Aoxin Q&M’s dental services make it resilient and well-positioned ride out the current downturn to capitalize on strategic opportunities in the post-COVID healthcare sector”. Mr Ryan San, Deputy Chief Executive Officer of Aoxin Q&M said, “The Group has been operating in a challenging environment, severely impacted by the recurring lockdowns of entire cities in the People’s Republic of China (“PRC”). We are keeping a close watch on the evolving COVID-19 situation in PRC, while managing our costs with strict discipline.” Revenue The Group’s revenue increased by RMB27.6 million or 20.8%, from RMB132.6 million in FY2020 to RMB160.2 million in FY2021, mainly due to the recovery in all business segments. Revenue from primary healthcare segment increased by 19.7% from RMB78.5 million in FY2020 to RMB93.9 million in FY2021. The increase in revenue were from our key hospitals in Shenyang and Dalian cities, and a polyclinic in Panjin city mainly due to increase in patients. Revenue from distribution of dental equipment and supplies segment achieved a significant growth of 24.8%. Revenue was RMB50.4 million in FY2021 as compared to RMB40.4 million in FY2020. There was a higher demand for dental supplies materials from government hospitals amidst a gradual economic recovery in China backed by rolling out of the COVID-19 vaccination in the country. Revenue from laboratory services segment increased by 15.9% to RMB15.9 million in FY2021 as compared to RMB13.7 million in FY2020 due to increase in demand of such services from the government dental hospitals in Shenyang City. EBITDA The Group’s EBITDA also increased from RM9.5 million in FY2020 to RMB13.9 million in FY2021. The increase in EBITDA was mainly attributable to higher revenue and better performance from key dental hospitals and polyclinics as well as higher sales for dental equipment and supplies. Despite a positive EBITDA of RMB13.9 million, the Group recorded a loss of RMB7.3 million due to salary increment and recruitment expenses, as well as higher other expenses, such as acquisition related fees for Acumen Diagnostics Pte. Ltd. (“Acumen Diagnostics”) and other tax expenses. Mr Ryan San, Deputy Chief Executive Officer of Aoxin Q&M added. “We are also hopeful that moving forward, our recent acquisition of a 49% stake in Acumen Diagnostics will improve the profitability and cashflow of the Group. With Acumen Diagnostics expertise in R&D and medical diagnostics we will be able to play a vital role in support of the Singapore government’s strategy of living with COVID-19. Concomitantly, this will also contribute to the growth of the Group.” Updates on associate – Acumen Diagnostics – Capabilities to Tackle Omicron COVID-19 Variant Acumen Diagnostics will continue to offer COVID-19 testing by polymerase chain reaction (“PCR”) for patients that require PCR test results and for travelers as Singapore opens its borders, as well as distribute COVID-19 antigen rapid tests (“ART”). It will also launch a panel of new PCR tests for infectious diseases, sepsis and cancer. On 3 December 2021, Acumen Diagnostics announced that its proprietary, locally-manufactured PCR test kits Acu-Corona 2.0 and Acu-Corona Duplex are able to detect COVID-19 positive cases infected with the Omicron variant. On 16 December 2021, Acumen Diagnostics announced that it has been granted a license by Ministry of Health, Singapore to provide offsite COVID-19 PCR swab services and serology sample collection at 100 clinics. Acumen Diagnostics will continue to roll out its testing services via the Q&M Dental Group Limited’s network of clinics, and also at its headquarters located at The Gemini, 41 Science Park Road, Singapore. Currently, Acumen Diagnostics has about 61 clinics providing the testing services island-wide. – Proposed listing on NASDAQ stock exchange in relation to Acumen Diagnostics Pte. Ltd. On 17 January 2022, Aoxin announced that the associated company of the Group, Acumen Diagnostics is exploring a proposed listing of its securities on the NASDAQ stock exchange in New York, USA. In this regard, Acumen Diagnostics has appointed UOB Kay Hian Private Limited to assist Acumen Diagnostics with the listing evaluation and all relevant preparatory work including the selection of professional advisers and underwriting banks in relation to the proposed listing and fund-raising exercise. Looking Forward Aoxin’s FY2021 results reflects the significant upturn in revenue as compared to FY2020 revenue which was the period when the COVID-19 pandemic in PRC was in a more serious phase. As the COVID-19 situation in the PRC continues to improve, we expect the Group’s revenue to correspondingly improve. In addition, the recent 49% acquisition of medical technology company, Acumen Diagnostics for S$29.4 million on 1 November 2021, will enhance the profitability of the Group going forward. The business environment is expected to remain challenging for the year ahead, as many countries including PRC struggle to contain the rapid spread of the COVID-19 virus demonstrated by new waves of infections. The Group will continue to focus on disciplined management of operating expenditures, costs and capital expenditures. The Group will continue to monitor its expenses and maximise cost efficiency for operations. Barring any unforeseen circumstances and further worsening of the COVID-19 situation such as ad-hoc lock down or temporary closures in cities where we operate, there are no known significant changes in the trends and competitive conditions of the industry in which the Group operates and no other major known factors or events that may adversely affect the Group in the next reporting period and the next 12 months. The Group will continue to monitor its operating expenses and maximise cost efficiency for operations. For more information, please see attached files or the below links:https://links.sgx.com/FileOpen/AoxinPressRelease-FY2021_final_23.2.22.ashx?App=Announcement&FileID=703172https://links.sgx.com/FileOpen/AXQM%20Announcement%20FY2021.ashx?App=Announcement&FileID=703171 This announcement has been reviewed by the Company’s sponsor, PrimePartners Corporate Finance Pte. Ltd. (the “Sponsor”). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “Exchange”) and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document. The contact person for the Sponsor is Ms. Lim Hui Ling, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, sponsorship@ppcf.com.sg About Aoxin Q&M Dental Group Limited (Stock Code: 1D4.SI) www.aoxinqm.com.sg Aoxin Q&M Dental Group Limited (“Aoxin Q&M” or together with its subsidiaries, the “Group”) is a leading provider of private dental services in the Liaoning Province, Northern People’s Republic of China (“PRC”). The Group operates 16 dental centres, comprising 10 dental polyclinics and 6 dental hospitals, located across 8 cities in Liaoning Province, namely Shenyang, Huludao, Panjin, Gaizhou, Zhuanghe, Jinzhou, Dalian and Anshan. We currently have 400 dental professionals, including 170 dentists, 180 dental surgery assistants and 50 laboratory technicians. A majority of the dental centres are accredited as Designated Medical Institutions of Medical Insurance. Additionally, the Group is engaged in the provision of dental laboratory services, as well as the distribution and sale of dental equipment and supplies in the Liaoning, Heilongjiang and Jilin Provinces in Northern PRC. Aoxin Q&M was listed on the Catalist board of the Singapore Exchange Securities Trading Limited on 26 April 2017. About Acumen Diagnostics Pte. Ltd. (www.acumen-research.com) Acumen Diagnostics Pte. Ltd. (“Acumen Diagnostics”) is a homegrown Singaporean, award-winning medical technology company. It is fully integrated with functions in research and development, manufacturing, as well as commercialisation of molecular diagnostics by distribution as well as conducting clinical laboratory testing services for (including but not limited to) infectious diseases, cancer, and COVID-19. It has also actively established frontline services such as COVID-19 on-site swabbing operations. Acumen Diagnostics is a 51% subsidiary of SGX-listed Q&M Dental Group (Singapore) Limited (SGX: 1D4.SI) and 49%-owned by SGX-listed Aoxin Q&M Dental Group Limited (SGX: QC7.SI). Media and Analysts: please contact below for more information: Waterbrooks Consultants Pte. Ltd.+65 6958 8008, query@waterbrooks.com.sgWayne Koo (M): +65 9338 8166, wayne.koo@waterbrooks.com.sgDerek Yeo (M): +65 9791 4707, derek@waterbrooks.com.sg

Read More
Posted on

Q&M Dental records historic highest-ever revenue and profit after tax for year ended 31 December 2021 and declares a full year dividend yielding 7%

– Revenue increases by 49% to S$205.6 million and Profit After Tax increases by 98% to S$39.4 million for FY2021– Core dental and medical clinics segment continues strong growth with 27% increase in revenue for FY2021– Declares fourth interim dividend of 1.0 Singapore cent per ordinary share for 4Q2021, giving total dividends of 4.0 Singapore cents per ordinary share for FY2021 and a dividend yield of 7%[1] SINGAPORE, Feb 23, 2022 – (ACN Newswire) – Q&M Dental Group (Singapore) Limited (“Q&M” or together with its subsidiaries, the “Group”), a leading private dental healthcare group in Asia, today reported the highest-ever revenue and profit after tax of S$205.6 million and S$39.4 million respectively for the financial year ended 31 December 2021 (“FY2021”). This is the best set of financials in Q&M’s 25-year history since its founding in 1996. Net profit after tax attributable to shareholders for FY2021 jumped 55% to S$30.5 million compared to S$19.7 million compared to a year ago. Quarterly Financial Performance since the start of Covid-19 (From 4Q2019) The Covid-19 pandemic had no impact on the Group’s core dental and medical clinics business segment and continued its strong growth trend. On a Quarterly basis, the Group’s revenue also recorded a steady increase from S$36.4 million in 4Q2019 to S$53.3 million in 4Q2021. FY2021 Financial Performance For the FY2021, total revenue improved by S$68.0 million or 49% from S$137.6 million to S$205.6 million. Revenue from dental and medical clinics increased by 27% to S$160.2 million. The increase was mainly due to higher revenue from existing and new dental clinics in Singapore. Revenue from medical laboratory and dental equipment & supplies segment jumped by 304% to S$45.4 million. The increase was mainly due to revenue from the Group’s Covid-19 medical laboratory business. The medical laboratory license from MOH was obtained in September 2020. The Group’s EBITDA for FY2021 correspondingly increased by 68% to S$63.3 million, from S$37.7 million in the previous period. The Group’s net profit after tax in FY2021 increased by 98% to S$39.4 million from the S$19.8 million recorded in FY2020. PATMI (Profit after tax attributable to Shareholders excluding Minorities) grew by 55% to S$30.5 million, from S$19.7 million in the previous period. Earnings per share increased to 3.23 Singapore cents for FY2021, from 2.09 Singapore cents in the previous period. As at 31 December 2021, the Group’s financial position remains strong with net assets of S$97.8 million, as well as cash and cash equivalents of S$47.6 million. Bank borrowings and financial liabilities amounted to S$83.7 million. Fourth interim Dividend The Group declares a fourth interim dividend of 1.0 Singapore cent per ordinary share for 4Q2021. In the last three quarters of 2021, the Group paid 1.0 Singapore cent in 1Q2021, 1.0 Singapore cent in 2Q2021 and 1.0 Singapore cent in 3Q2021. The total dividends work out to 4.0 Singapore cents for FY2021 translating to a 7% dividend yield based on closing share price of 56.5 cents and a dividend payout ratio of 113%. The 4Q2021 dividend will be paid on 24 March 2022. Operational Update – Growth & Expansion in medical clinics As at 31 December 2021, the Group has 136 dental clinics as compared to 118 in 31 December 2020, an increase of 18. The Group’s number of medical clinics in Singapore remained unchanged at 5. (See Table 1) In Singapore, the Group’s number of dental clinics in Singapore grew to 97 in FY2021 from 83 in FY2020. The Group opened 15 new clinics and consolidated 1 clinic in Singapore in 2021 resulting in a net increase of 14 clinics. (See Table 2) Similarly, for overseas, the number of dental clinics has increased to 39 in FY2021, as compared to 35 previously. 38 dental clinics are in Malaysia and 1 dental clinic is in the People’s Republic of China (“PRC”). The locations of the dental clinics in Malaysia are 15 in Johor, 18 in Kuala Lumpur and 5 in Malacca. (See Table 3). To support this growth, the Group has also increased its total number of dentists to 270 as at 31 December 2021, as compared to 250 a year ago. Updates on subsidiary – Acumen Diagnostics Pte Ltd The Group continues to focus on investment opportunities in sectors that are synergistic and aligned with its business strategy. Associate Company Aoxin Q&M Dental Group Limited (“Aoxin”)’s recent acquisition of a 49% shareholding of Acumen Diagnostics Pte. Ltd. (“Acumen Diagnostics”), raised Q&M’s effective interest in Acumen Diagnostics to 67% from 51% in October 2021. With 1 scientist, 16 medical technologists and 36 other staff, Acumen Diagnostics’ technical capabilities and infrastructure in molecular diagnostics, enables it to do research and development, manufacturing, as well as clinical laboratory testing. – Capabilities to Tackle Omicron Covid-19 Variant For Acumen Diagnostics, the Group will continue to offer COVID-19 testing by polymerase chain reaction (“PCR”) for patients that require PCR test results and for travelers as Singapore opens its borders, as well as distribute COVID-19 antigen rapid tests (“ART”). It will also launch a panel of new PCR tests for infectious diseases, sepsis and cancer. On 11 November 2021, Acumen Diagnostics announced that it has been granted the license by Ministry of Health, Singapore to provide door-to-door COVID-19 PCR home swab services. On 3 December 2021, Acumen Diagnostics announced that its proprietary, locally-manufactured PCR test kits Acu-Corona 2.0 and Acu-Corona Duplex are able to detect COVID-19 positive cases infected with the Omicron variant. On 16 December 2021, Acumen Diagnostics announced that it has been granted a license by Ministry of Health, Singapore to provide offsite COVID-19 PCR swab services and serology sample collection at 100 clinics. Acumen Diagnostics will continue to roll out its testing services via the Group’s network of clinics, and also at its headquarters located at The Gemini, 41 Science Park Road, Singapore. Currently, the Company has about 61 clinics providing the testing services island-wide. – Appoints UOB Kay Hian Private Limited as Arranger to Explore NASDAQ Listing On 17 January 2022, Q&M announced that Acumen Diagnostics is exploring a proposed listing of its securities on the NASDAQ stock exchange in New York, USA. Acumen Diagnostics has appointed UOB Kay Hian Private Limited to assist Acumen Diagnostics with the listing evaluation and all relevant preparatory work including the selection of professional advisers and underwriting banks in relation to the proposed NASDAQ listing and fundraising exercise. Looking Forward – Expansion Plans Dr Ng Chin Siau, said “Q&M will embark on 4 pillars of growth. Firstly, expansion of our core dental business in Singapore, Malaysia as well as South East Asia and China for sustainable growth. “Our Group intends to open at least 30 dental clinics a year from 2021 onwards in Singapore and Malaysia for the next 10 years.” Secondly, the use of medical technology such as our proprietary Artificial Intelligence Guided Clinical Decision Support System to provide the most effective and suitable treatment plans for patients This will enable us to scale up consistency and quality throughout our network clinics. Thirdly, expand our clinical testing laboratory business to test Covid-19 and other diseases such as dengue sepsis and other bacterial pathogens. Fourthly, invest in medical and healthcare business that will enhance our shareholder’s value such as Acumen Diagnostic.” Q&M Group will continue to execute our business plans outlined below: 1. Expansion of network of dental clinics in Singapore, Malaysia and Southeast Asia Q&M will focus on its operations in Singapore and has initiated a strategy of intensive organic growth for its dental clinics in Singapore. It will expand its team of dentists to support the future growth of its operations in Singapore. The Group intends to open at least 30 dental clinics a year for the next 10 years from 2021 onwards in Singapore and Malaysia and continue to look for opportunities to expand its business through the opening of new dental clinics in Southeast Asia. The eventual number of dental outlets will depend on available opportunities, pertinent market conditions and the evolving Covid-19 situation. 2. Expansion into private dental healthcare market in China Q&M’s main thrust of expansion in China is through organic growth to develop a new and sustainable growth pillar that can yield long term value for the Group. 3. Artificial Intelligence Guided Clinical Decision Support System (AI-GCDSS) Q&M will continue to develop, invest, and optimise its proprietary digital Artificial Intelligence (AI) Guided Clinical Decision Support System to provide the most effective and suitable treatment plans for patients. The Group believes it is well-positioned to cater to patients’ rising demand for primary and higher value specialist dental healthcare services. 4. Medical Laboratory Q&M will focus on rolling out its clinical testing laboratory’s pipeline of new tests including PCR assays for dengue sepsis and the identification of bacterial pathogens and their associated antibiotics resistance in pneumonia and bloodstream infections. Looking Forward Barring any unforeseen circumstances, such as a rapid worsening of the Covid-19 situation in Singapore and Malaysia, there are no known significant changes in the trends and competitive conditions of the industry in which the Group operates and no other major known factors or events that may adversely affect the Group in the next reporting period and the next 12 months. [1] Based on closing share price of 56.5 cents as at 17 February 2022 Please see links for PDF documents from SGXNET.https://links.sgx.com/FileOpen/QnM_FY%202021_PRESS_RELEASE.ashx?App=Announcement&FileID=703150https://links.sgx.com/FileOpen/QnM_4Q2021_Result_Announcement.ashx?App=Announcement&FileID=703149 About Q&M Dental Group (Singapore) Limited (QC7.SI) www.QandMDental.com.sg Q&M Dental Group (Singapore) Limited (“Q&M” or together with its subsidiaries, the “Group”) is a leading private dental healthcare group in Asia. The Group owns the largest network of private dental outlets in Singapore, operating 98 dental outlets across the country. Underpinned by about 270 experienced dentists, 7 doctors and over 350 supporting staff, the Group sees an average of 40,000 patient visits a month in Singapore. The Group also operates 5 medical clinics and a dental supplies and equipment distribution company. Outside of Singapore, the Group has 38 dental clinics and a dental supplies and equipment distribution company in Malaysia, as well as a dental clinic in the People’s Republic of China (“PRC”). Q&M is also the substantial shareholder of Aoxin Q&M Dental Group Limited, a dental Group listed on the Catalist board of the Singapore Exchange, which operates dental clinics and hospitals primarily in the North- eastern region of the PRC. The Group aims to expand its operations geographically and vertically through the value chain in Malaysia, the PRC and within ASEAN. In 2018, the Group made inroads into the development of advanced technology in healthcare with the establishment of EM2AI Pte. Ltd. (“EM2AI”, formerly known as Q&M Dental AI Pte. Ltd.). EM2AI focuses on developing an Artificial Intelligence (AI) ethical enhanced guided treatment plan. In 2019, the Group expanded into dental postgraduate education with the establishment of the Q&M College of Dentistry. It offers Singapore’s first private postgraduate diploma programme in clinical dentistry. In 2020, the Group also expanded into the medical laboratories and research industry with the incorporation of Acumen Diagnostics Pte. Ltd. (“Acumen Diagnostics”). Acumen Diagnostics currently focuses on the manufacture, sale and distribution of COVID-19 diagnostic test kits, as well as COVID-19 testing. The Group was listed on the Mainboard of the Singapore Exchange Securities Trading Limited (“SGX- ST”) on 26 November 2009. For more information, please contact:Waterbrooks Consultants Pte LtdTel: +65 6958 8008 (M) +65 9690-4959 email: query@waterbrooks.com.sgWayne Koo – wayne.koo@waterbrooks.com.sg (M) +65 933 88166Derek Yeo – derek@waterbrooks.com.sg

Read More
Posted on

EC Healthcare Acquires Multi-Disciplinary Medical Services Centers

HONG KONG, Feb 16, 2022 - (ACN Newswire via SEAPRWire.com) - EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce that the Group enters into a sales and purchase agreement to acquire entire issued share capital of Excellent Power Investments Limited (the "Target Company") for a total consideration of HK$68 million in cash.The Target Company owns Health & Care Dental Services Limited, Health & Care Dental Clinic Limited, Health & Care (Macau) Dental Group Limited, Qualigenics Medical Limited, AmMed Cancer Center (Central) Limited and Humphrey & Partners Medical Services Management Limited and has a long-standing history in providing comprehensive healthcare services in Hong Kong and Macau since 2000. The medical services that the Target Company provide within its 12 clinics including dental services, chronic disease management services, specialty services, imaging and diagnostic services. It also administrates a comprehensive medical network of over 250 affiliated clinics providing general practitioners, specialists and physiotherapy services. According to the unaudited consolidated financial information for financial year ended 31 March 2021, the revenue and profit after tax of the Target Company amounted to HK$130.49 million and HK$10.12 million, respectively.Leveraging on the Target Company's business layout in Hong Kong and Macau and specially its expertise in dental field, the Group will gain its first foothold in the professional dental services of Macau, and further strengthen its medical expertise in chronic disease management. This acquisition complements the Groups' strategy of consolidating its leadership in discretionary medical market in the Greater Bay Area. Upon completion of the acquisition, the Group will have 12 additional medical centers also further enlarge its fulltime registered doctors and network doctors team. Ms. Ada Wong, Executive Director and Chief Strategy Officer and Chief Investment Officer of EC Healthcare said, "The Group is delighted to expand its medical services in Macau, which will further enhance our market share and leading position in the dental and chronic disease management market in the Greater Bay Area. Looking ahead, the Group will be well-positioned to continue exploiting the reciprocal business interaction among our diverse medical specialty disciplines to create more value and further develop its enclosed healthcare ecosystem."About EC Healthcare EC Healthcare is Hong Kong's largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group's high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism. The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, primary care clinics jointly established with Tencent Doctorwork, chiropractic services centre SPINE Central, New York Spine and Physiotherapy Center NYMG, health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, a comprehensive dental centre UMH DENTAL CARE, a diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic SPECIALISTS CENTRAL and NEW MEDICAL CENTER, obstetrics and gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, specialists central, a paediatric center PRIME CARE, cardiology center HONG KONG INTERNATIONAL CARDIOLOGY CENTER, PathLab Medical Laboratories, a professional hair care center HAIR FOREST, Ophthalmology Center VIVID EYE and EC Veterinary Hospital and Imaging Center.*According to independent research conducted by Frost and Sullivan in terms of revenue in 2019 and 2020For further information, please contact: iPR Ogilvy Limited Callis Lau / Lorraine Luk / Charmaine IpTel: (852) 2136 6952 / 2169 0467 / 3920 7649Fax: (852) 3170 6606 Email: ech@iprogilvy.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Acumen Diagnostics granted Ministry of Health COVID-19 offsite PCR testing license, up to 100 sites island-wide

SINGAPORE, Dec 16, 2021 - (ACN Newswire via SEAPRWire.com) - Homegrown medical technology Company, Acumen Diagnostics Pte. Ltd. ("Acumen Diagnostics" or the "Company"), a 51% owned subsidiary of Q&M Dental Group (Singapore) Limited ("Q&M Dental") and 49% owned by Aoxin Q&M Dental Group Limited ("Aoxin Q&M Dental"), today announced that it has been granted a license by the Ministry of Health, Singapore to provide offsite COVID-19 polymerase chain reaction ("PCR") swab services and serology sample collection.The Company will roll out its testing services via Q&M Dental's network of clinics, and also at Acumen Diagnostics' headquarters located at The Gemini, 41 Science Park Road, Singapore.Dr Ong Siew Hwa, Chief Executive Officer & Chief Scientist of Acumen Diagnostics and Executive Director of Aoxin Q&M Dental, said "Vaccination coupled with a robust testing regime remains the best strategy to tackle the virus enabling a safe and more sustainable re-opening of the economy.PCR tests remain the gold standard for accurately detecting COVID-19 cases and with the potential higher transmissibility of new variants such as Omicron, testing needs to be deployed quickly and provide highly accurate results to control the spread of the virus."With the onset of the Omicron variant and Vaccinated Travel Lane arrangements with more countries being added, the Company will ramp up its COVID-19 PCR testing services in anticipation of the increased demand for PCR testing, at an initial 10 Q&M Dental outlets plus the Company's headquarters, by 31 December 2021. See Annex A below for details of the 10 Q&M Dental outlets. More sites will be added in the next few months to the rest of the Q&M Dental network, with a potential capacity to activate 100 sites island-wide.Dr Ng Chin Siau, Chief Executive Officer of Q&M Dental said, "Through Q&M Dental's extensive network of clinics, with capacity to roll out to 100 sites island-wide, we as a Group are committed to provide highly accurate and accessible PCR tests to make COVID-19 testing hassle-free and convenient for all Singapore residents.And with one of the most competitive pricing available in Singapore, we will ensure that our tests remain affordable for everyone who needs to be tested. We will continue to do our part to contribute to the national effort to combat the COVID-19 virus and progress towards living with endemic COVID-19."Those who require their PCR test results on urgent basis can also visit Acumen Diagnostics' headquarters at The Gemini, 41 Science Park Road, Singapore. With its headquarters located in close proximity to the Company's two laboratories, PCR test results will be available in as early as 4 hours. For an additional fee, the Company also provides doorstep PCR testing services to your home or workplace.Acumen Diagnostics possesses deep technical capabilities and the supporting infrastructure in molecular diagnostics, spanning R&D, manufacturing, and clinical laboratory testing, with 2 laboratories that are able to process over 7,000 COVID-19 diagnostics tests daily.Recently, on 3 December 2021, Acumen Diagnostics also announced that its proprietary, locally-manufactured PCR test kits Acu-Corona 2.0 and Acu-Corona Duplex are able to detect COVID-19 positive cases infected with the Omicron variant. In addition to detecting COVID-19 positive cases infected with the Delta variant, the Company's proprietary PCR test kits are able to pick-up COVID-19 positive cases infected with the Omicron variant as well.Annex A: Initial testing sites at Acumen Diagnostics and Q&M Dental branches by 31 December 2021S/N - Acumen HQ & Q&M Dental Outlet - Address - TelephoneHQ - Acumen Diagnostics (Headquarters) - 41 Science Park Road #01-02 Gemini (Lobby B) (S) 117610 - 6980 00801 - Canberra - Blk 126 Canberra Street #01-03 Multi Storey Car Park (S) 750126 - 6518 31152 - Geylang - 1 Lorong 22 Geylang #01-01 Grandview Suites (S) 398664 - 6741 20713 - Jurong East - 2 Jurong East Street 21 #02-61A IMM Building (S) 609601 - 6980 39994 - Jurong - Blk 353 Jurong East Street 31 #01-107 Yuhua Place (S) 600353 - 6980 38685 - Kim Seng - 1 Kim Seng Promenade #03-117 Great World City (S) 237994 - 6734 06036 - Kim Tian - Blk 126 Kim Tian Road #01-03 Kim Tian Green (S) 160126 - 6979 76687 - North Bridge - 107 North Bridge Road #B1-37/38 Funan Mall (S) 179105 - 6979 92968 - Potong Pasir - 51 Upper Serangoon Road #03-10/11 The Poiz Centre (S) 347697 - 6968 51319 - Sembawang Way - Blk 355 Sembawang Way #01-07 (S) 750355 - 6235 278210 - Tanjong Katong - 11 Tanjong Katong Road #B1-13 Kinex (S) 437157 - 6241 6562About Acumen Diagnostics Pte. Ltd. (www.acumen-research.com)Acumen Diagnostics Pte. Ltd. ("Acumen Diagnostics") is a homegrown Singaporean, award-winning medical technology company. It is fully integrated with functions in research and development, manufacturing, as well as commercialisation of molecular diagnostics by distribution as well as conducting clinical laboratory testing services for (including but not limited to) infectious diseases, cancer, and COVID-19. It has also actively established frontline services such as COVID-19 on-site swabbing operations.Acumen Diagnostics is a 51% subsidiary of SGX-listed Q&M Dental Group (Singapore) Limited (SGX: 1D4.SI) and 49%-owned by SGX-listed Aoxin Q&M Dental Group Limited (SGX: QC7.SI).About Q&M Dental Group (Singapore) Limited (QC7.SI) (www.QandMDental.com.sg)Q&M Dental Group (Singapore) Limited ("Q&M" or together with its subsidiaries, the "Group") is a leading private dental healthcare group in Asia. The Group owns the largest network of private dental outlets in Singapore, operating 90 dental outlets across the country. Underpinned by about 270 experienced dentists, 7 doctors and more than 350 supporting staff, the Group sees an average of 40,000 patient visits a month in Singapore. The Group also operates 5 medical clinics and a dental supplies and equipment distribution company.Outside of Singapore, the Group has 38 dental clinics and a dental supplies and equipment distribution company in Malaysia, as well as a dental clinic in the People's Republic of China ("PRC"). Q&M is also the substantial shareholder of Aoxin Q&M Dental Group Limited, a dental Group listed on the Catalist board of the Singapore Exchange, which operates dental clinics and hospitals primarily in the Northeastern region of the PRC. The Group aims to expand its operations geographically and vertically through the value chain in Malaysia, the PRC and within ASEAN.In 2018, the Group made inroads into the development of advanced technology in healthcare with the establishment of EM2AI Pte. Ltd. ("EM2AI", formerly known as Q&M Dental AI Pte. Ltd.). EM2AI focuses on developing an Artificial Intelligence (AI) ethical enhanced guided treatment plan.In 2019, the Group expanded into dental postgraduate education with the establishment of the Q&M College of Dentistry. It offers Singapore's first private postgraduate diploma programme in clinical dentistry.In 2020, the Group also expanded into the medical laboratories and research industry with the incorporation of Acumen Diagnostics Pte. Ltd. ("Acumen Diagnostics"). Acumen Diagnostics currently focuses on the manufacture, sale and distribution of COVID-19 diagnostic test kits, as well as COVID19 testing.The Group was listed on the Mainboard of the Singapore Exchange Securities Trading Limited ("SGXST") on 26 November 2009.About Aoxin Q&M Dental Group Limited (Stock Code: 1D4.SI) (www.aoxinqm.com.sg)Aoxin Q&M Dental Group Limited ("Aoxin Q&M Dental" or together with its subsidiaries, the "Group") is a leading provider of private dental services in the Liaoning Province, Northern People's Republic of China ("PRC"). The Group operates 16 dental centres, comprising 10 dental polyclinics and 6 dental hospitals, located across 8 cities in Liaoning Province, namely Shenyang, Huludao, Panjin, Gaizhou, Zhuanghe, Jinzhou, Dalian and Anshan. We currently have 400 dental professionals, including 170 dentists, 180 dental surgery assistants and 50 laboratory technicians. A majority of the dental centres are accredited as Designated Medical Institutions of Medical Insurance. Additionally, the Group is engaged in the provision of dental laboratory services, as well as the distribution and sale of dental equipment and supplies in the Liaoning, Heilongjiang and Jilin Provinces in Northern PRC.Aoxin Q&M Dental was listed on the Catalist board of the Singapore Exchange Securities Trading Limited on 26 April 2017.Media and Analysts: please contact below for more information:Waterbrooks Consultants Pte. Ltd.+65 6958 8008, query@waterbrooks.com.sgWayne Koo (M): +65 9338 8166, wayne.koo@waterbrooks.com.sgDerek Yeo (M): +65 9791 4707, derek@waterbrooks.com.sg Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

EC Healthcare Acquires Hong Kong Dental Services Chain

HONG KONG, Nov 30, 2021 - (ACN Newswire via SEAPRWire.com) - EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce that the Group enters into an agreement to acquire 55% of the issued share capital of Bayley & Jackson Dental Surgeons Limited (the "Target Company"), for a total consideration of approximately HK$129 million, which shall be satisfied as to approximately HK$ 119 million in cash and as to approximately HK$10 million by the allotment and issue of Consideration Shares at HK$ 12.557 per share.The Target Company is a dental services chain operator with a long-standing history in Hong Kong providing dental services in Hong Kong since 1958. As of the date of this announcement, the Target Company operates seven dental clinics located in Central, Tsim Sha Tsui, Mong Kok, Repulse Bay and Clean Water Bay of Hong Kong with 32 practicing dentists including dental general practitioners and specialists. According to the unaudited financial information for the year ended 31 March 2021, the profit after tax of the Target Company amounted to HK$15.18 million. Upon completion of the acquisition, the financial result of the Target Company will be consolidated into the consolidated financial statement of the Group. The Target Company guarantees to the Group with an aggregate net profit for the seven financial years ending 31 March 2029 should be no less than HK$120 million.The Target Company has long-standing history, unique and well recognized brand and owns an extensive loyal corporate client base serving companies such as The Hong Kong Polytechnic University, Cathay Pacific Airways Limited and MTR Corporation Limited. Leveraging on its operational excellence and efficiencies, the Group will benefit from the Target Company's brand equity and continue to empower the Group's existing dental-related medical assets, improve the overall efficiency of the Group's dental medical assets and enhance the service capability as a multi-specialty medical service provider, thus further enhancing the customer retention rate and the overall profitability of the Group.Mr. Levin Lee, Executive Director and Chief Finance Officer of EC Healthcare said, "This acquisition will help expand the Group's existing dental business, deepen and enhance the service capability of the Group's medical services segment, thereby further strengthening its leadership in the discretionary medical market. Looking ahead, the Group will be well-positioned to continue exploiting the reciprocal business interaction between dental and medical aesthetic businesses to create more value. Meanwhile, the Group will complement with advancement in information technology, branding, and service to build the enclosed healthcare ecosystem and to further consolidate the healthcare market."About EC Healthcare EC Healthcare is Hong Kong's largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group's high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism.The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, primary care clinics jointly established with Tencent Doctorwork, chiropractic services centre SPINE Central, New York Spine and Physiotherapy Center NYMG, health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, a comprehensive dental centre UMH DENTAL CARE, a diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic SPECIALISTS CENTRAL and NEW MEDICAL CENTER, obstetrics and gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, specialists central, a paediatric center PRIME CARE, cardiology center HONG KONG INTERNATIONAL CARDIOLOGY CENTER, PathLab Medical Laboratories, a professional hair care center HAIR FOREST, Ophthalmology Center VIVID EYE and EC Veterinary Hospital and Imaging Center.*According to independent research conducted by Frost and Sullivan in terms of revenue in 2019 and 2020For further information, please contact: iPR Ogilvy Limited Callis Lau / Lorraine Luk / Charmaine IpTel: (852) 2136 6952 / 2169 0467 / 3920 7649Fax: (852) 3170 6606 Email: ech@iprogilvy.com Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Q&M Dental net profit surges 154% to S$35.4M for nine months ended 30 September 2021

SINGAPORE, Nov 11, 2021 - (ACN Newswire via SEAPRWire.com) - Q&M Dental Group (Singapore) Limited ("Q&M" or together with its subsidiaries, the "Group"), a leading private dental healthcare group in Asia, today reported net profit after tax attributable to shareholders of S$27.3 million for the nine months ended 30 September 2021 ("9M2021"), and net profit after tax attributable to shareholders S$9.5 million for the three months ended 30 September 2021 ("3Q2021").Quarterly Financial Performance since 4Q2019The Group has grown stronger compared to the pre-Covid-19 period. The Group's revenue rose by 58% from S$36.5 million in 4Q2019 to S$57.7 million in 3Q2021, or 6.78% quarterly compounded growth from 4Q2019 to 3Q2021. Profit before tax grew 112% from S$7.9 million in 4Q2019 to S$16.7 million in 3Q2021, or 11% quarterly compounded growth from 4Q2019 to 3Q2021.Dr Ng Chin Siau, Chief Executive Officer of Q&M added, "The Group's strong financial performance and accomplishments continue to be propelled by our corporate values and philosophy of "Improving Oneself & Unity". We believe that every individual within Q&M strives for continual improvement, and seeks knowledge and excellence in all their endeavours, and this has enabled the Group to attain sustainable growth."For the 9M2021, revenue contribution from dental and medical clinics increased by 36% to S$116.6 million. Revenue contribution from medical laboratory and dental equipment & supplies segment surged by 334% to S$35.7 million. The Group's EBITDA also increased 104% to S$52.9 million, from S$25.9 million in the previous period. Earnings per share increased to 2.89 Singapore cents, from 1.46 Singapore cents in the previous period.The Group's net profit after tax increased by 154% to S$35.4 million from S$13.9 million in the previous period. Profit after tax attributable to owners of the parent grew by 98% to S$27.3 million, from S$13.8 million in the previous period.For 3Q2021, revenue contribution from dental and medical clinics increased to S$39.3 million and contribution from medical laboratory and dental equipment & supplies segment also soared 932% to S$18.4 million, due to the same reasons stated above. EBITDA also increased to S$21.4 million, up by 121% from the previous period. The Group's net profit after tax increased by 175% to S$13.9 million, from S$5.1 million in the previous period. Profit after tax attributable to owners of the parent grew by 69% to S$9.5 million, from S$5.6 million in the previous period.As at 30 September 2021, the Group financial position remains strong with net assets of S$121.5 million with cash and cash equivalents of S$49.6 million. Bank borrowings and finance leases amounted to S$83.8 million.DividendThe Group proposes an interim dividend of 1.0 Singapore cent per ordinary share for 3Q2021. Earlier in the year, the Group paid 1.0 Singapore cent in 1Q2021 and 1.0 Singapore cent in 2Q2021. The 3Q2021 dividends declared, will be paid to all shareholders on 3rd December 2021.Growth & Expansion In OperationsAs at 30 September 2021, the Group's number of dental clinics in Singapore has grown to 90, from 81 as at 30 September 2020. Similarly in Malaysia, the number of dental clinics has increased to 38, as compared to 33 previously. In order to support this growth, the Group has also increased its total number of dentists to 270 as at 30 September 2021, as compared to 250 previously.Most recently in 3Q2021, the Company opened 3 new clinics in Singapore, in Canberra, Bedok Reservoir and IMM shopping mall.The Group also continues to focus on its investments in opportunities in allied sectors, with its Associated Company, Aoxin Q&M Dental Group Limited ("Aoxin")'s recent acquisition of 49% shareholding of Acumen Diagnostics Pte. Ltd. ("Acumen Diagnostics"), which raised Q&M's effective interest in Acumen Diagnostics from 51% to 67%. With 3 scientists and 21 technicians, Acumen Diagnostics' technical capabilities and infrastructure in molecular diagnostics, spans research and development, manufacturing, and clinical laboratory testing.Outlook & Further Expansion PlansBarring any unforeseen circumstances and any worsening of the Covid-19 situation, which may necessitate reimposing curbs on economic activity, the Group is optimistic on its business outlook and prospects moving forward.For Acumen Diagnostics, the Group will continue to offer Covid-19 testing by PCR for patients that require PCR test results and for travellers as Singapore opens its borders, as well as distribute Covid- 19 antigen rapid tests (ART). The Group will also develop a panel of new PCR tests in infectious diseases, sepsis and cancer.[1] Based on closing share price of 55.5 cents as at 9 November 2021About Q&M Dental Group (Singapore) Limited (QC7.SI) www.QandMDental.com.sgQ&M Dental Group (Singapore) Limited ("Q&M" or together with its subsidiaries, the "Group") is a leading private dental healthcare group in Asia. The Group owns the largest network of private dental outlets in Singapore, operating 90 dental outlets across the country. Underpinned by about 270 experienced dentists, 7 doctors and more than 350 supporting staff, the Group sees an average of 40,000 patient visits a month in Singapore. The Group also operates 5 medical clinics and a dental supplies and equipment distribution company.Outside of Singapore, the Group has 38 dental clinics and a dental supplies and equipment distribution company in Malaysia, as well as a dental clinic in the People's Republic of China ("PRC"). Q&M is also the substantial shareholder of Aoxin Q&M Dental Group Limited, a dental Group listed on the Catalist board of the Singapore Exchange, which operates dental clinics and hospitals primarily in the North- eastern region of the PRC. The Group aims to expand its operations geographically and vertically through the value chain in Malaysia, the PRC and within ASEAN.In 2018, the Group made inroads into the development of advanced technology in healthcare with the establishment of EM2AI Pte. Ltd. ("EM2AI", formerly known as Q&M Dental AI Pte. Ltd.). EM2AI focuses on developing an Artificial Intelligence (AI) ethical enhanced guided treatment plan.In 2019, the Group expanded into dental postgraduate education with the establishment of the Q&M College of Dentistry. It offers Singapore's first private postgraduate diploma programme in clinical dentistry.In 2020, the Group also expanded into the medical laboratories and research industry with the incorporation of Acumen Diagnostics Pte. Ltd. ("Acumen Diagnostics"). Acumen Diagnostics currently focuses on the manufacture, sale and distribution of COVID-19 diagnostic test kits, as well as COVID- 19 testing.The Group was listed on the Mainboard of the Singapore Exchange Securities Trading Limited ("SGX- ST") on 26 November 2009.This release can be found at https://bit.ly/3FlndVFFor more information, please contact:Waterbrooks Consultants Pte LtdTel: +65 6958 8008 M: +65 9690-4959 email: query@waterbrooks.com.sgWayne Koo - wayne.koo@waterbrooks.com.sg M +65 933 88166Derek Yeo - derek@waterbrooks.com.sg Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Aoxin Q & M acquires 49% stake in Acumen Diagnostics for S$29.4m

SINGAPORE, Oct 4, 2021 - (ACN Newswire via SEAPRWire.com) - Aoxin Q & M Dental Group Ltd (SGX: 1D4.SI) ("Aoxin Q & M") and Q & M Dental Group (Singapore) Limited (SGX: QC7.SI) ("Q & M"), announced today that Aoxin Q & M will acquire 49% of Acumen Diagnostics Pte. Ltd. ("Acumen Diagnostics") for a consideration of S$29.4 million. Acumen Diagnostics has a preliminary valuation of S$60 million.Diagram 1: Shareholdings upon completion of acquisition of Acumen Diagnostics by Aoxin Q & MAcquisition & ValuationAoxin Q & M has entered into a conditional sale and purchase deed with Acumen Diagnostics' shareholders, Dr Ong Siew Hwa and Acumen Holdings Pte. Ltd., to acquire their 49% shareholding in Acumen Diagnostics.The preliminary valuation of Acumen Diagnostics (upon completion of a restructuring exercise involving Acumen Research Laboratories Pte. Ltd.) is S$60 million, derived based on the latest financial statements of Acumen Diagnostics, taking into account the earnings and growth prospects of its business.The purchase consideration for the shares is S$29.4 million, to be satisfied by way of the allotment and issuance of new ordinary shares in the capital of Aoxin Q & M at an issue price of S$0.231 per share, credited as fully paid-up shares in the capital of Aoxin Q & M which will rank pari passu in all respects with the existing shares in the capital of Aoxin Q & M.Upon completion of the acquisition, Aoxin Q & M will directly hold 49% of Acumen Diagnostics, with Q & M holding the balance of 51%. Q & M's total effective ownership of Acumen Diagnostics will thus amount to 67.15%, based on its 32.95% equity stake in Aoxin Q & M. See diagram 1 below.Diagram 1: Shareholdings upon completion of acquisition of Acumen Diagnostics by Aoxin Q & Mhttps://www.acnnewswire.com/topimg/Low_aoxinqm20211004.jpgRationale of Acquisition & ValuationThe acquisition and integration of the Acumen Diagnostics business into Aoxin Q & M is timely and strategic, allowing Aoxin Q & M to enter the medical diagnostics business in Singapore and capture a significant portion of the testing capacity market in conducting frequent and widespread testing, in support of Singapore's national COVID-19 strategy.The proposed acquisition would also improve the profitability of Aoxin Q & M through the sharing of profits and improve the cashflow position of Aoxin Q & M as and when Acumen Diagnostics declares dividends down the line. Over time, Aoxin Q & M will benefit from potential commercial, operational and costs synergies between itself and Acumen Diagnostics. The Board of Directors of Aoxin Q & M believes that the proposed acquisition will enhance the long-term interests of Aoxin Q & M and its shareholders.With over 80% of the population now vaccinated, Singapore is moving towards a "living with COVID-19" strategy or treating COVID-19 as an "endemic" disease. In a live address in May 2021, the Prime Minister, Lee Hsien Loong, laid out the government's three-pronged strategy of "vaccination, contact-tracing and testing" as the country starts to reopen.Mr. Ryan San, Deputy Chief Executive Officer of Aoxin Q & M, said "Learning to live with COVID-19 in the new "normal" requires a deliberate and rapid response from both the public and private sector. We believe this acquisition is an important and strategic one for Aoxin Q & M as the availability of good quality performing test kits and testing services will be an important cog in the overall national response to treating and living with COVID-19. While the acquisition will be immediately profit accretive, we see this as a fantastic opportunity to assist in providing an essential capability to Singapore in this next phase of tackling the COVID-19 pandemic."Dr Ng Chin Siau, Chief Executive Officer of Q & M said, "Strategic business development is a top priority for Q & M as we look to drive sustainable growth and further bolster and balance our pipeline with innovations and businesses that contribute to our responses to the global COVID-19 pandemic. Q & M supports this transaction, and this transaction is likely to be beneficial to Q & M and its shareholders and financially strengthen Q & M and Aoxin Q & M in the mid and long term.""Acumen Diagnostics' innovative products and capabilities have yielded exciting growth that complements and strengthens our company's overall portfolio and pipeline and holds the potential to build upon our proud legacy in the healthcare sector. To date, it is able to handle 7,000 COVID-19 tests daily and has the ability to ramp up for more tests, if called upon by Health Promotion Board ("HPB") or Ministry of Health ("MOH")." added Dr Ng.Dr Ong Siew Hwa, Chief Executive Officer & Chief Scientist, Acumen Diagnostics said, "We are very excited about joining the Aoxin Q & M family and the new growth opportunities both in Singapore and China, that this acquisition will present. Our technical capabilities and infrastructure in molecular diagnostics, spanning R&D, manufacturing, clinical laboratory testing, positions us well to create value in the generation of both new patent assets and, revenues, through the sales of test kits and provision of testing services."Acumen Diagnostics will continue to operate independently post acquisition, driving forward a continued focus on its mission, employees, stakeholders, and community. Acumen Diagnostics will continue to be led by Dr Ong Siew Hwa and her team who will provide their unique expertise and technical know-how to manage the business. In the near term, Acumen Diagnostics will roll out in its clinical testing laboratory a pipeline of new tests, including PCR assays for dengue, sepsis and, identification of bacterial pathogens and their associated antibiotics resistance in pneumonia and bloodstream infections. Its longer-term plans include development of vaccines.This press release is to read in conjunction with the SGXNET announcements dated 4 October 2021.Link to SGXNET announcement https://bit.ly/3uAHpi2About Acumen Diagnostics Pte. Ltd.Acumen Diagnostics Pte. Ltd. ("Acumen Diagnostics") is a Singapore-grown, award-winning medical technology company. It is fully integrated with functions in research and development, manufacturing, as well as commercialisation of molecular diagnostics by distribution as well as conducting clinical laboratory testing services for (including but not limited to) infectious diseases, cancer, and COVID-19. It has also actively established frontline services such as COVID-19 on-site swabbing operations. For more information, please visit the company website at www.acumen-research.com.About Aoxin Q & M Dental Group Limited (Stock Code: 1D4.SI)Aoxin Q & M Dental Group Limited ("Aoxin Q & M" or together with its subsidiaries, the "Group") is a leading provider of private dental services in the Liaoning Province, Northern People's Republic of China ("PRC"). The Group operates 16 dental centres, comprising 10 dental polyclinics and 6 dental hospitals, located across 8 cities in Liaoning Province, namely Shenyang, Huludao, Panjin, Gaizhou, Zhuanghe, Jinzhou, Dalian and Anshan. We currently have 400 dental professionals, including 170 dentists, 180 dental surgery assistants and 50 laboratory technicians. A majority of the dental centres are accredited as Designated Medical Institutions of Medical Insurance. Additionally, the Group is engaged in the provision of dental laboratory services, as well as the distribution and sale of dental equipment and supplies in the Liaoning, Heilongjiang and Jilin Provinces in Northern PRC.Aoxin Q & M was listed on the Catalist board of the Singapore Exchange Securities Trading Limited on 26 April 2017. For more information, please visit the company website at www.aoxinqm.com.sg.About Q & M Dental Group (Singapore) Limited (QC7.SI)Q & M Dental Group (Singapore) Limited ("Q & M" or together with its subsidiaries, the "Group") is a leading private dental healthcare group in Asia.The Group owns the largest network of private dental outlets in Singapore, operating 87 dental outlets across the country. Underpinned by about 230 experienced dentists and more than 350 supporting staff, the Group sees an average of 40,000 patient visits a month in Singapore. The Group also operates 5 medical clinics and a dental supplies and equipment distribution company.Outside of Singapore, the Group has 37 dental clinics and a dental supplies and equipment distribution company in Malaysia, as well as a dental clinic in the People's Republic of China ("PRC"). Q & M is also the substantial shareholder of Aoxin Q & M Dental Group Limited, a dental Group listed on the Catalist board of the Singapore Exchange, which operates dental clinics and hospitals primarily in the North-eastern region of the PRC. The Group aims to expand its operations geographically and vertically through the value chain in Malaysia, the PRC and within ASEAN.In 2018, the Group made inroads into the development of advanced technology in healthcare with the establishment of EM2AI Pte. Ltd. ("EM2AI", formerly known as Q & M Dental AI Pte. Ltd.). EM2AI focuses on developing AI-powered solutions in diagnosis and treatment planning.In 2019, the Group expanded into dental postgraduate education with the establishment of the Q & M College of Dentistry. It offers Singapore's first private postgraduate diploma programme in clinical dentistry.In 2020, the Group also expanded into the medical laboratories and research industry with the incorporation of Acumen Diagnostics Pte. Ltd. ("Acumen Diagnostics"). Acumen Diagnostics currently focuses on the manufacture, sale and distribution of COVID-19 diagnostic test kits, as well as COVID-19 testing.The Group was listed on the Mainboard of the Singapore Exchange Securities Trading Limited ("SGX- ST") on 26 November 2009. For further information on the Group, please visit www.QandMDental.com.sgFor more information, please contact: Waterbrooks Consultants Pte LtdWayne Koo (M): +65 9631 3602, wayne.koo@waterbrooks.com.sgDerek Yeo (M): +65 9791 4707, derek@waterbrooks.com.sg Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Dentist struck off S’pore dental register for making false Chas claims

SINGAPORE - Dentist Teo Eu Gene, who was jailed last year for having submitted false claims for dental procedures, has been struck off the official dental register. He will not be permitted to practise as a dentist in Singapore for at least three years. After this period, he can apply for his name to be restored in the register, said the Singapore Dental Council in a statement on Friday (June 25). Last year, Teo became the first person to be jailed for cheating the Government through the Community Health Assist Scheme (Chas). He was sentenced to 46 weeks' jail after being convicted of 25 charges of making false Chas claims. These claims were for dental procedures between 2014 and 2015. Teo's actions caused two polyclinic groups - SingHealth Polyclinics and National Healthcare Group Polyclinics - that process and reimburse Chas claims on behalf of the Ministry of Health to wrongfully disburse more than $18,000. On Friday, the Singapore Dental Council said it held on April 12 a disciplinary inquiry against Teo, who previously practised at Phoenix Dental Surgery clinics. The disciplinary committee noted that Teo's dishonest conduct and convictions seriously impinged upon the reputation of the profession. As Teo's case was apparently the first to be brought before the disciplinary committee, it was imperative to set the appropriate benchmark in emphasising that such cases must be dealt with severely, said the council. Teo has been ordered to pay the costs and expenses of, and incidental to, the proceedings, including costs of counsel to the Singapore Dental Council. His removal from the Register of Dentists took effect on Wednesday (June 23). The council urged all dental professionals to be cognisant of the laws and regulations governing dental practices. It added that professionals should comply with the provisions of the code of ethics of the profession as well as directives and guidelines issued by the Ministry of Health. More on this topic   Related Story Jesselton Dental Centre to be terminated from Chas scheme for numerous improper claims   Related Story 2 dentists charged with cheating over $54,000 in fake Chas and Medisave claims

Read More
Posted on

Orchard dental clinic to be taken off Chas

A dental clinic in the Orchard area will be removed from the Community Health Assist Scheme (Chas) after it was found to have made numerous improper claims for government subsidies. These claims made by Jesselton Dental Centre at Pacific Plaza exceeded the allowed limit for Chas subsidies and were not accompanied by proper supporting documentation, the Ministry of Health (MOH) said yesterday. "Audits on Jesselton Dental Centre conducted in late 2018 to 2019 revealed severe non-compliance," it said. Of the over 200 claims for Chas subsidies from the clinic that were audited, about 96 per cent were found to be non-compliant, said the ministry. The termination was issued on Dec 10 and will take effect from Saturday. MOH advised affected patients to visit other nearby Chas-accredited dental clinics instead. In response to queries from The Straits Times, a Jesselton Dental Centre spokesman said yesterday that the claims were made by an administrative staff and a member of the clinic's management team between 2017 and 2018. Both of them were let go immediately after they were found to have made the claims. "We are working alongside the authorities to remedy the situation. Our patients always come first," the spokesman said. MOH said it was informed in April by the clinic in Scotts Road that its ownership and licensee had changed hands from Resilient Healthcare Group to Alliance Management Group. "This cessation of Resilient Healthcare Group as the licensee, coupled with the extent of Jesselton Dental Centre's non-compliance, made the termination of the clinic from Chas necessary," it said. "MOH will continue to investigate the clinic even with the change in ownership." The clinic can still treat patients, provided its dentists hold valid registration and practising certificates from the Singapore Dental Council, but the treatment it provides will not be covered by Chas subsidies. "MOH encourages patients to actively engage their doctors and dentists if they have any queries on their bills," said the ministry. "We also remind healthcare professionals to uphold a high standard of professionalism and adhere to their ethical code and ethical guidelines." In October 2019, two dentists from Phoenix Dental Surgery clinic became the first to be charged with cheating through Chas. Teo Eu Gene pleaded guilty to 25 counts of cheating by submitting false Chas claims for dental procedures and was sentenced to 46 weeks' jail. His former colleague, Andy Joshua Warren, faced similar charges. To check Chas claims made on their behalf, Chas, Pioneer Generation and Merdeka Generation card holders can log in to the "My Chas" module on the Chas website, or call the Chas hotline on 1800-275-2427. They can also contact MOH, if they come across any suspicious or unusual claims, by calling the ministry on 1800-225-4122 or by e-mailing MOH_QSM@moh.gov.sg

Read More